SONORX
LOE ApproachingNDAORALSUSPENSION
Approved
Oct 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SONORX is an oral suspension approved by FDA in 1998 as an NDA product manufactured by Bracco. The mechanism of action, pharmacologic class, and specific indications are not publicly documented in available data. The product's formulation as an oral suspension suggests systemic delivery for a condition treatable via this route.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand team likely in defensive or transition planning mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SONORX currently has zero linked job openings, reflecting its late-lifecycle stage and mature market position. Career opportunities are likely limited to defensive commercial roles focused on market share retention and cost management rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on SONORX at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.